Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
11 févr. 2021 07h00 HE
|
Retrotope
LOS ALTOS, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Emerald Health Pharmaceuticals’ Scientific Team Leads Cannabinoid Research Showing Potential to Impact Neurodegenerative Diseases
20 sept. 2017 07h00 HE
|
Emerald Health Pharmaceuticals Inc.
SAN DIEGO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a development-stage company focused on treating life-threatening diseases through cannabinoid science, is...
Emerald Health Pharmaceuticals to Treat Life-Threatening Diseases with Novel Synthetic Cannabinoid-Derived Molecules
14 sept. 2017 09h00 HE
|
Emerald Health Pharmaceuticals Inc.
SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP) today announced its mission to discover, develop and commercialize novel synthetic cannabinoid-derivative drug...
Elsevier Recognizes Alzheimer's - Brain Awareness Month with New Book, "A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease"
06 juin 2017 04h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - June 06, 2017) - Elsevier, the information analytics company specializing in science and health, today announced A Roadmap for Curing Cancer, Alzheimer's, and...
Breakthrough: Paradigm Shift in Monitoring and Improving Brain Health
30 mai 2017 08h00 HE
|
Posit Science
SAN FRANCISCO, May 30, 2017 (GLOBE NEWSWIRE) -- Dr. Michael Merzenich will unveil a revolutionary approach to monitoring, maintaining and improving brain health at the world’s most prestigious...
Elsevier Announces Timely New Book, "Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease"
01 nov. 2016 04h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - November 01, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Drug...
MYOS Corporation Announces 1-for-50 Reverse Stock Split Following Five Consecutive Quarters of Market Expansion and Revenue Growth
10 févr. 2014 07h30 HE
|
MYOS Corp
CEDAR KNOLLS, NJ--(Marketwired - Feb 10, 2014) - MYOS Corporation (OTCBB: MYOSD), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of...
At National Tay-Sachs & Allied Diseases Science Symposium, Leading Neurodegenerative Disease Researchers Present Breakthroughs
06 avr. 2011 05h52 HE
|
National Tay-Sachs & Allied Diseases Association
BOSTON, April 6, 2011 (GLOBE NEWSWIRE) -- Breakthroughs in crossing the blood-brain barrier could lead to new treatments for Tay-Sachs, Canavan and other neurodegenerative diseases. The findings were...